230 related articles for article (PubMed ID: 29292059)
1. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
Faraci M; Bagnasco F; Leoni M; Giardino S; Terranova P; Subissi L; Di Duca M; Di Martino D; Lanino E
Biol Blood Marrow Transplant; 2018 May; 24(5):1088-1093. PubMed ID: 29292059
[TBL] [Abstract][Full Text] [Related]
2. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
3. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
[TBL] [Abstract][Full Text] [Related]
4. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.
Saito B; Fukuda T; Yokoyama H; Kurosawa S; Takahashi T; Fuji S; Takahashi N; Tajima K; Kim SW; Mori SI; Tanosaki R; Takaue Y; Heike Y
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1148-1155. PubMed ID: 18804045
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?
Pichler H; Fritsch G; König M; Daxberger H; Glogova E; Pötschger U; Breuer S; Lawitschka A; Güclü ED; Karlhuber S; Holter W; Haas OA; Lion T; Matthes-Martin S
Br J Haematol; 2016 Jun; 173(6):905-17. PubMed ID: 26996395
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):208-11. PubMed ID: 12812663
[TBL] [Abstract][Full Text] [Related]
7. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
9. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran.
Alimoghaddam K; Ghaffari H; Foroughi F; Chardouli B; Sanaat Z; Bahar B; Mousavi A; Iravani M; Ghavamzadeh A
Arch Iran Med; 2006 Apr; 9(2):99-103. PubMed ID: 16649348
[TBL] [Abstract][Full Text] [Related]
10. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of hematopoietic chimerism after non-myeloablative allogeneic peripheral blood stem cell transplantation].
Chen BA; Xiong HX; Ding JH; Su EB; Zhao G; Wang J; Gao C; Sun YY; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):313-7. PubMed ID: 16638205
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Real-Time PCR Analysis of Chimerism in T Cell Subsets as an Early Predictor of Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation.
Guz K; Nasiłowska B; Tomaszewska A; Orzińska A; Smolarczyk-Wodzyńska J; Krzemienowska M; Hałaburda K; Przybylski M; Jędrzejczak WW; Mariańska B; Brojer E
Ann Transplant; 2015 Dec; 20():720-8. PubMed ID: 26632547
[TBL] [Abstract][Full Text] [Related]
14. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
15. Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases.
Umeda K; Adachi S; Tanaka S; Miki M; Okada K; Hashii Y; Inoue M; Cho Y; Koh K; Goto H; Kajiwara R; Hyakuna N; Kato K; Morio T; Yabe H;
Pediatr Blood Cancer; 2016 Dec; 63(12):2221-2229. PubMed ID: 27554591
[TBL] [Abstract][Full Text] [Related]
16. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
18. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
19. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting.
Afram G; Simón JAP; Remberger M; Caballero-Velázquez T; Martino R; Piñana JL; Ringden O; Esquirol A; Lopez-Corral L; Garcia I; López-Godino O; Sierra J; Caballero D; Ljungman P; Vazquez L; Hägglund H
Med Oncol; 2018 Apr; 35(6):79. PubMed ID: 29696461
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.
Yang F; Lu D; Hu Y; Huang X; Huang H; Chen J; Wu D; Wang J; Wang C; Han M; Chen H
Ann Transplant; 2017 Jun; 22():384-401. PubMed ID: 28652564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
